Assessing the Budget Impact and Economic Outcomes of the Introduction of Daclatasvir + Asunaprevir and Sofosbuvir/Ledipasvir for the Treatment of Chronic Hepatitis C Virus Infection in Japan.
about
Assessing the Budget Impact and Economic Outcomes of the Introduction of Daclatasvir + Asunaprevir and Sofosbuvir/Ledipasvir for the Treatment of Chronic Hepatitis C Virus Infection in Japan.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Assessing the Budget Impact an ...... is C Virus Infection in Japan.
@en
type
label
Assessing the Budget Impact an ...... is C Virus Infection in Japan.
@en
prefLabel
Assessing the Budget Impact an ...... is C Virus Infection in Japan.
@en
P2093
P1476
Assessing the Budget Impact an ...... is C Virus Infection in Japan.
@en
P2093
Gail Wygant
Phil McEwan
Samantha Webster
Sari Mishina
Thomas Ward
P356
10.1016/J.VHRI.2016.10.002
P577
2016-12-24T00:00:00Z